Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus SODIUM ROSE BENGAL I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus SODIUM ROSE BENGAL I 131.
FLUORODOPA F18 vs SODIUM ROSE BENGAL I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical